New Research: Being Overweight Increases the Risk for These 2 Cancers
May 28, 2024 / Obesity / Cancer / Breast Cancer / Metabolic Syndrome
New research links obesity and metabolic syndrome with higher risks of endometrial and breast cancers, particularly in postmenopausal women. Each 11-pound weight gain increases cancer risk by 11%.
From fibrosis and cancer to obesity, Alzheimer’s and aging: New paper reveals broad potential of TNIK as a therapeutic target
May 28, 2024 / AI / Drug Discovery / Fibrosis Treatment / Aging Related Diseases
Insilico Medicine’s research highlights TNIK’s potential as a therapeutic target for aging-related diseases like fibrosis, cancer, obesity, and Alzheimer’s, guiding new therapeutic development.
MRC awards two medical research units at University of Cambridge £30m in funding
May 28, 2024 / MRC Funding / Cambridge / Public Health Improvments / Metabolic Disease
The Medical Research Council awarded £30m to the University of Cambridge’s MRC Biostatistics Unit and Metabolic Diseases Unit to advance public health research until 2029.
Why GLP-1 Medications Alone Won’t Solve the Obesity Crisis
May 28, 2024 / GLP-1 / Obesity / Weight Loss Drugs / Metabolic Health
GLP-1 medications, while effective in weight loss and metabolic health, require integration with lifestyle changes for lasting success in combating obesity, emphasizes Dr. Brent Baldasare.
Experts disagree on whether prediabetes is overdiagnosed. What you should know
May 28, 2024 / Prediabettes diagnosis / Diabetes / Metabolic Syndrome
Experts debate the diagnosis of prediabetes, with some cautioning against overdiagnosis due to potential stress and costs, while others advocate early detection to prevent progression to serious health issues.
Discovery of promising protein candidate opens new avenues for treating metabolic disorders
May 28, 2024 / NLP / Metabolic Disorder / Obesity / MAFLD
Researchers at the University of Saskatchewan discovered that the peptide nesfatin-1-like peptide (NLP) lowers lipid accumulation in human liver cells, offering new treatment possibilities for metabolic disorders like obesity and MAFLD.
Low vitamin D levels linked to higher diabetes risk in older adults, study finds
May 27, 2024 / Vitamin D / Diabetes / Elderly Health
A study published in Nutrients links low vitamin D levels to an increased risk of type 2 diabetes in older adults, highlighting the importance of maintaining adequate vitamin D levels for diabetes prevention.
How Metabolic Syndrome, Obesity Impact Breast Cancer Incidence, Mortality Risk
May 27, 2024 / Metabolic Syndrome / Obesity / Breast Cancer / Women’s Health
A study from the Women’s Health Initiative found that metabolic syndrome increases the risk of poor-prognosis breast cancer and higher mortality, while obesity raises the overall incidence of good-prognosis breast cancer in postmenopausal women.
The serum tenascin C level is a marker of metabolic disorder-related inflammation affecting pancreatic cancer prognosis
May 26, 2024 / Metabolic Disorder / Cancer / Obesity / Pancreatic Cancer
High serum tenascin C (TNC) levels, associated with obesity-related metabolic disorders, predict poor prognosis in pancreatic cancer patients, highlighting its role as a marker of metabolic disorder-related inflammation affecting cancer progression.
Update on the STING signaling pathway in developing nonalcoholic fatty liver disease
May 24, 2024 / NAFLD Treatment / Metabolic Disorders / Liver Disease / Hepatic Inflammation
Research highlights the STING signaling pathway’s role in NAFLD progression through hepatic inflammation and metabolic disturbances, presenting it as a promising therapeutic target.
Eli Lilly Pumps $5.3B More Into Site for Making Metabolic Meds Zepbound & Mounjaro
May 24, 2024 / Eli Lilly / Investment / Mounjaro / Drug Manufacturing / Metabolic Disorder
Eli Lilly is investing an additional $5.3 billion in its Indiana site to produce Zepbound and Mounjaro, boosting total investment to $9 billion, with production expected to start in 2026.
Type 2 diabetes treatment found to impact fungal community in human gut
May 24, 2024 / Type 2 Diabetes / Gut Microbiome
A study found that type 2 diabetes and its treatment, metformin, cause significant changes in the human gut mycobiome, highlighting the need to consider pharmaceutical impacts in microbiome research.
New study further illuminates ability of cancer drug to lower blood sugar
May 23, 2024 / Type 2 Diabetes / Insulin
A study finds that a flavonoid-rich diet can reduce the risk of type 2 diabetes by up to 28%, highlighting the benefits of foods like tea, berries, and apples.
Chemical toxin exposure in the womb linked to greater health risks for children ages 6 to 11
May 23, 2024 / Prenatal Chemical Exposure / Endocrine Disruptors / Metabolic Syndrome / Obesity / Pregnancy
Prenatal exposure to endocrine-disrupting chemicals increases the risk of metabolic syndrome, obesity, and related health issues in children aged 6 to 11, a new study reports.
New Biomarkers Discovered for Early Prediction of Kidney Failure in Type 1 Diabetes Patients
May 23, 2024 / Kidney Failure / Type 1 Diabetes / Biomarkers
City of Hope researchers identified new DNA methylation biomarkers for predicting kidney failure in type 1 diabetes patients, potentially enabling noninvasive early detection, as reported in Science Translational Medicine.
More Weight Loss With Anti-Obesity Meds and Hormone Therapy?
May 23, 2024 / Hormone Therapy / Anti-obesity Drug / Menopause / Weight Loss
A study found postmenopausal women using hormone therapy experienced significantly greater weight loss when treated with semaglutide compared to those not on hormone therapy, highlighting the potential impact of menopause on the effectiveness of anti-obesity drugs.
Click Therapeutics Accelerates Expansion into Obesity and Cardiometabolic Disease With Acquisition of the Assets of Better Therapeutics, Inc.
May 22, 2024 / Digital Therapeutics / Obesity / Cardiometabolic Disease / Click Therapeutics
A study found that UV exposure increases appetite but prevents weight gain by raising norepinephrine levels, decreasing leptin levels, and inducing the browning of subcutaneous fat, suggesting new obesity treatment possibilities.
Obesity and metabolic syndrome affect breast cancer risks differently, study reports
May 16, 2024 / Liver Cancer / Fatty Liver Diease
A study shows that obesity increases breast cancer incidence, while metabolic syndrome raises breast cancer mortality. Managing both can improve breast cancer outcomes.
HealthWell Foundation Launches Broad Fund to Assist Patients Living with Metabolic Dysfunction-Associated Steatohepatitis (MASH)
May 28, 2024 / HealthWell foundation / MASH / Nonalcoholic Fatty Liver Disease
The HealthWell Foundation launched a fund to provide up to $8,000 in financial assistance for medication, insurance, and treatment costs to underinsured patients with metabolic dysfunction-associated steatohepatitis (MASH).
Researchers decipher mechanisms of liver regeneration
May 23, 2024 / MASLD / MASH / Single-cell Analysis Liver / Chronic Liver Disease
Researchers from BIH and University of Cambridge uncovered liver regeneration mechanisms during chronic liver disease, revealing processes that aid repair but may lead to cancer. Findings from single-cell analyses and cultured organoids were published in Nature.